骨髓增生异常综合征患者β_2-MG和LDH检测的临床价值  

Clinical value ofβ_2-MG and LDH determination in the patients with myelodysplastic syndrome

作　　者：张冬清[1] 林静华[1] 周焕槟[1] 王雪华[1] 焦晓阳[1] 

机构地区：[1]汕头大学医学院第一附属医院检验科,广东汕头515041

出　　处：《癌变．畸变．突变》2012年第4期302-304,共3页Carcinogenesis,Teratogenesis & Mutagenesis

摘　　要：目的:探讨骨髓增生异常综合征(myelodysplastic syndrome,MDS)患者血清β_2-微球蛋白(β_2-microglobulin,β_2-MG)和乳酸脱氢酶(lactic dehydrogenase,LDH)检测的临床价值。方法:采用放射免疫法测定血清β_2-MG,速率法检测LDH,比较两者在30例健康体检者和45例不同亚型MDS患者中的水平,并对两者均增高和均正常的MDS患者进行生存分析。结果:各组MDS患者血清β_2-MG水平均明显高于正常对照组(P<0.01),其中难治性贫血伴原始细胞过多-Ⅱ(refractory anemia with excessive blastsⅡ,RAEB-Ⅱ)组明显高于难治性贫血(refractory anemia,RA)、难治性血细胞减少伴有多系发育异常(refractory cytopenia with multilineagedysplasia,RCMD)和难治性贫血伴原始细胞过多-Ⅰ(refractory anemia with excessive blastsⅠ,RAEB-Ⅰ)组,差异均有统计学意义(P均<0.01);RAEB-Ⅰ、RAEB-Ⅱ组血清LDH水平明显高于RA、RCMD组(P<0.01);血清LDH、β_2-MG均增高的患者中位生存期明显短于两者均正常者(P<0.01)。结论:联合检测血清β_2-MG和LDH水平,对于MDS的诊断、分型及预后分析具有重要的临床价值。OBJECTIVE： To explore the clinical value of the determination of serum β2-microglobulin（β 2- MG） and lactic dehydrogenase（LDH） in patients with myelodysplastic syndrome （MDS）. METHODS ： Serum β2-MG was determined by radioimmunoassay. Serum LDH was detected by velocity method. The levels of β2-MG and LDH were compared between 30 healthy people and 45 patients with different types of MDS groups. The survival analysis of MDS patients with high and normal level of β2-MG and LDH was made and compared. RESULTS： The levels of β2-MG in all of MDS groups were significantly higher than that in control group （P〈0.01）. β2-MG in RAEB-II group were significantly higher than that in RA, RCMD and RAEB-I group（P〈0.01）. The levels of LDH in RAEB-I, RAEB-II groups was significantly higher than that in RA and RCMD groups （P〈0.01）. Median survival time of the patients with high levels of LDH and β2-MG was significantly shorter than that of the patients with normal LDH and β2-MG （P〈0.01）. CONCLUSION： Combined determination of the levels of serum β2-MG and LDH could confer important clinical significance in the diagnosis, classification and prognosis of MDS.

关 键 词：骨髓增生异常综合征 Β2-微球蛋白 乳酸脱氢酶 中位生存期 

分 类 号：R446.112[医药卫生—诊断学]